TG Therapeutics (NASDAQ:TGTX) Cut to Hold at ValuEngine

ValuEngine cut shares of TG Therapeutics (NASDAQ:TGTX) from a buy rating to a hold rating in a research report released on Wednesday morning, ValuEngine reports.

Other research analysts also recently issued research reports about the stock. HC Wainwright restated a buy rating on shares of TG Therapeutics in a report on Friday, May 29th. BidaskClub raised shares of TG Therapeutics from a hold rating to a buy rating in a research report on Tuesday, June 23rd. Zacks Investment Research upgraded shares of TG Therapeutics from a hold rating to a buy rating and set a $11.00 target price on the stock in a report on Thursday, March 26th. B. Riley reiterated a buy rating and set a $37.00 price target on shares of TG Therapeutics in a research note on Monday, June 15th. Finally, Cantor Fitzgerald increased their price objective on TG Therapeutics from $19.00 to $35.00 and gave the stock an overweight rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $35.00.

Shares of TG Therapeutics stock opened at $24.15 on Wednesday. The business has a 50-day simple moving average of $19.26 and a 200 day simple moving average of $14.46. TG Therapeutics has a one year low of $4.95 and a one year high of $24.76. The company has a quick ratio of 1.39, a current ratio of 1.39 and a debt-to-equity ratio of 1.01.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.12). TG Therapeutics had a negative net margin of 124,230.27% and a negative return on equity of 2,937.74%. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. Research analysts anticipate that TG Therapeutics will post -1.38 EPS for the current year.

In other TG Therapeutics news, Director William James Kennedy sold 7,745 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $18.27, for a total value of $141,501.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 13.20% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Great West Life Assurance Co. Can bought a new position in TG Therapeutics in the 4th quarter valued at $59,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of TG Therapeutics by 37.5% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,032 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 1,645 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in shares of TG Therapeutics by 9.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 7,400 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 660 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its position in TG Therapeutics by 47.4% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,327 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 3,000 shares during the period. Finally, Redhawk Wealth Advisors Inc. purchased a new stake in TG Therapeutics during the first quarter worth about $98,000. 58.88% of the stock is currently owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Recommended Story: What type of investment options does a Roth IRA provide?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.